Advertisement

Molecular Biology Reports

, Volume 41, Issue 5, pp 3279–3286 | Cite as

TLR3 plays significant roles against hepatitis B virus

  • Masoud Karimi-Googheri
  • Mohammad Kazemi ArababadiEmail author
Article

Abstract

Hepatitis B virus (HBV) as the main prevalent infectious agent, play important roles in inducing severe liver diseases. Previous studies demonstrated that during prolonged forms of hepatitis B infection including chronic, asymptomatic and occult forms, patients are unable to eradicate HBV from hepatocytes completely. The main mechanisms responsible for development of the forms of hepatitis B are yet to be identified. Investigators suggested that the various genetic and immunological parameters of the patients may are responsible for resulting in the prolonged infection forms. It has been evidenced that TLRs play key roles in inducing appropriate immune responses, against viral infections. Therefore, these molecules can be considered as crucial sensors for HBV detection to induce immune responses against this virus. It has also been documented that the TLR3 detects intracellular viral dsRNA and subsequently activates NF-κB via the TRIF pathway. Therefore, impaired TLR3 expression may result in inappropriate immune responses against HBV which is reported in prolonged forms of hepatitis B. This review collected the recent information regarding the important roles of TLR3 in immune responses against HBV and also the status of TLR3 expression and its genetic variations in prolonged forms of HBV infections.

Keywords

Prolonged HBV infection TLR3 Polymorphism dsRNA 

Abbreviation

TLR

Toll like receptor

PAMP

Pathogen associated molecular patterns

HBV

Hepatitis B virus

MYD88

Myeloid differentiation primary response

IRAK1

Interleukin-1 receptor associated kinase-1

TRAF6

TNF receptor associated factor

NF-κB

Nuclear factor kappa-light-chain-enhancer of activated B cells

DNMT-1

DNA methyltransferase 1

TAK1

Transforming growth factor b-activated kinase 1

MAPK

Mitogen-activated protein kinase

AP-1

Activator protein 1

PBMC

Peripheral blood mononuclear cell

NADPH

Nicotinamide adenine dinucleotide phosphate

MHC

Major histocompatibility complex

IRF

Interferon regulatory factor

Notes

Acknowledgments

This project was granted by the Rafsanjan University of Medical Sciences.

References

  1. 1.
    Assar S, Arababadi MK, Ahmadabadi BN, Salehi M, Kennedy D (2012) Occult hepatitis B virus (HBV) infection: a global challenge for medicine. Clin Lab 58(11–12):1225–1230PubMedGoogle Scholar
  2. 2.
    Ayoobi F, Hassanshahi G, Zainodini N, Khorramdelazad H, Arababadi MK, Kennedy D (2013) Reduced expression of TRIF in chronic HBV infected Iranian patients. Clin Res Hepatol Gastroenterol. doi: 10.1016/j.clinre.2012.11.005 PubMedGoogle Scholar
  3. 3.
    Khorramdelazad H, Hassanshahi G, Ahmadabadi BN, Arababadi MK (2012) High serum levels of TGF-beta in Iranians with chronic HBV infection. Hepat Mon 12(11):e7581. doi: 10.5812/hepatmon.7581 PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Chan HL, Jia J (2011) Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 26(Suppl 1):131–137CrossRefPubMedGoogle Scholar
  5. 5.
    Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Rezvani ME (2009) Association of exon 9 but not intron 8 VDR polymorphisms with occult HBV infection in south-eastern Iranian patients. J Gastroenterol Hepatol 25(1):90–93CrossRefPubMedGoogle Scholar
  6. 6.
    Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD (2009) Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 27:27Google Scholar
  7. 7.
    Michielsen P, Ho E (2011) Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg 74(1):4–8PubMedGoogle Scholar
  8. 8.
    Ahmadabadi BN, Hassanshahi G, Arababadi MK, Leanza C, Kennedy D (2012) The IL-10 promoter polymorphism at position -592 is correlated with susceptibility to occult HBV infection. Inflammation 35(3):818–821. doi: 10.1007/s10753-011-9381-x CrossRefPubMedGoogle Scholar
  9. 9.
    Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H (2007) TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 100(5):1301–1312. doi: 10.1002/jcb.21119 CrossRefPubMedGoogle Scholar
  10. 10.
    Carpenter S, O’Neill L (2009) Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J 422:1–10CrossRefPubMedGoogle Scholar
  11. 11.
    Yu M, Lam J, Rada B, Leto TL, Levine SJ (2011) Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3–TRIF–RIP1-dependent signaling: roles for dual oxidase 2-and caspase-dependent pathways. J Immunol 186(2):1180–1188PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633):640CrossRefPubMedGoogle Scholar
  13. 13.
    Lai Y, Yi G, Chen A, Bhardwaj K, Tragesser BJ, Rodrigo AV, Zlotnick A, Mukhopadhyay S, Ranjith-Kumar CT, Kao CC (2011) Viral double-strand RNA-binding proteins can enhance innate immune signaling by toll-like Receptor 3. PLoS One 6(10):e25837. doi: 10.1371/journal.pone.0025837 PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Arababadi MK, Ahmadabadi BN, Kennedy D (2012) Current information on the immunological status of occult hepatitis B infection. Transfusion 52(8):1819–1826CrossRefPubMedGoogle Scholar
  15. 15.
    Arababadi MK, Pourfathollah AA, Jafarzadeh AA, Hassanshahi G (2010) Serum levels of Interleukin (IL)-10 and IL-17A in occult HBV infected South-East Iranian patients. Hepat Mon 10(1):31–35PubMedCentralPubMedGoogle Scholar
  16. 16.
    Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30(1):16–34CrossRefPubMedGoogle Scholar
  17. 17.
    Kawai T, Akira S (2006) Innate immune recognition of viral infection. Nat Immunol 7(2):131–137CrossRefPubMedGoogle Scholar
  18. 18.
    Beutler B (2008) Toll-like receptor genes. Genetic susceptibility to infectious diseases, pp. 165Google Scholar
  19. 19.
    Youn HS, Lee JY, Saitoh SI, Miyake K, Kang KW, Choi YJ, Hwang DH (2006) Suppression of MyD88-and TRIF-dependent signaling pathways of toll-like receptor by (S)-epigallocatechin-3-gallate, a polyphenol component of green tea. Biochem Pharmacol 72:850–859CrossRefPubMedGoogle Scholar
  20. 20.
    Muzio M, Bosisio D, Polentarutti N, D’amico G, Stoppacciaro A, Mancinelli R, van’t Veer C, Penton-Rol G, Ruco LP, Allavena P (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164(11):5998–6004CrossRefPubMedGoogle Scholar
  21. 21.
    Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR (2005) The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA 102(31):10976–10980PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Choe J, Kelker MS, Wilson IA (2005) Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309(5734):581CrossRefPubMedGoogle Scholar
  23. 23.
    Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5(2):190–198. doi: 10.1038/ni1028 CrossRefPubMedGoogle Scholar
  24. 24.
    Nicodemus CF, Berek JS (2010) TLR3 agonists as immunotherapeutic agents. Immunotherapy 2(2):137–140. doi: 10.2217/imt.10.8 CrossRefPubMedGoogle Scholar
  25. 25.
    Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413(6857):732–738. doi: 10.1038/35099560 CrossRefPubMedGoogle Scholar
  26. 26.
    Kariko K, Ni H, Capodici J, Lamphier M, Weissman D (2004) mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279(13):12542–12550. doi: 10.1074/jbc.M310175200 CrossRefPubMedGoogle Scholar
  27. 27.
    Matsumoto M, Seya T (2008) TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60(7):805–812. doi: 10.1016/j.addr.2007.11.005 CrossRefPubMedGoogle Scholar
  28. 28.
    Gauzzi MC, Del Corno M, Gessani S (2010) Dissecting TLR3 signalling in dendritic cells. Immunobiology 215(9–10):713–723. doi: 10.1016/j.imbio.2010.05.008 CrossRefPubMedGoogle Scholar
  29. 29.
    McBride S, Hoebe K, Georgel P, Janssen E (2006) Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol 177(9):6122–6128CrossRefPubMedGoogle Scholar
  30. 30.
    Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, Hsu HY, Chang MH (2012) Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan. J Infect Dis 206(5):662–668. doi: 10.1093/infdis/jis420 CrossRefPubMedGoogle Scholar
  31. 31.
    Chang WJ, Toledo-Pereyra LH (2012) Toll-like receptor signaling in liver ischemia and reperfusion. J Invest Surg 25(4):271–277. doi: 10.3109/08941939.2012.687802 CrossRefPubMedGoogle Scholar
  32. 32.
    Szatmary Z (2012) Molecular biology of toll-like receptors. Gen Physiol Biophys 31(4):357–366. doi: 10.4149/gpb_2012_048 CrossRefPubMedGoogle Scholar
  33. 33.
    Li X, Jiang S, Tapping RI (2010) Toll-like receptor signaling in cell proliferation and survival. Cytokine 49(1):1–9. doi: 10.1016/j.cyto.2009.08.010 PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Tuosto L (2011) NF-kappaB family of transcription factors: biochemical players of CD28 co-stimulation. Immunol Lett 135(1–2):1–9. doi: 10.1016/j.imlet.2010.09.005 CrossRefPubMedGoogle Scholar
  35. 35.
    Alsharifi M, Lobigs M, Regner M, Lee E, Koskinen A, Mullbacher A (2005) Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection. J Immunol 175(7):4635–4640CrossRefPubMedGoogle Scholar
  36. 36.
    Maire M, Parent R, Morand AL, Alotte C, Trepo C, Durantel D, Petit MA (2008) Characterization of the double-stranded RNA responses in human liver progenitor cells. Biochem Biophys Res Commun 368(3):556–562. doi: 10.1016/j.bbrc.2008.01.123 CrossRefPubMedGoogle Scholar
  37. 37.
    Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z (2010) Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 91(Pt 8):2080–2090. doi: 10.1099/vir.0.020552-0 CrossRefPubMedGoogle Scholar
  38. 38.
    An BY, Xie Q, Lin LY, Shen HC, Jia NN, Wang H, Guo SM, Yu H, Guo Q (2007) Expression of Toll-like receptor 3 on peripheral blood dendritic cells in HBeAg positive patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 15(10):729–733PubMedGoogle Scholar
  39. 39.
    Ondondo BO, Brunham RC, Harrison WG, Kinyari T, Sheth PM, Mugo NR, Cohen CR (2009) Frequency and magnitude of Chlamydia trachomatis elementary body–and heat shock protein 60–stimulated interferon γ responses in peripheral blood mononuclear cells and endometrial biopsy samples from women with high exposure to infection. J Infect Dis 199(12):1771–1779CrossRefPubMedGoogle Scholar
  40. 40.
    Tjwa ET, van Oord GW, Biesta PJ, Boonstra A, Janssen HL, Woltman AM (2012) Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol 86(8):4102–4109. doi: 10.1128/JVI.07000-11 PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Wang K, Liu H, He Y, Chen T, Yang Y, Niu Y, Chen H, Chen Y, Liu J, Ye F, Lin S, Zhao Y (2010) Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol 71(10):950–956. doi: 10.1016/j.humimm.2010.07.013 CrossRefPubMedGoogle Scholar
  42. 42.
    An BY, Xie Q, Wang H, Jia NN, Shen HC, Cai W, Yu H, Guo Q (2008) Expression and significance of interferon regulatory factor 3 of peripheral blood dendritic cells in HBV-infected patients. World Chin J Digest 16(17):1873–1879Google Scholar
  43. 43.
    Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z (2012) HBsAg inhibits IFN-alpha production in plasmacytoid dendritic cells through TNF-alpha and IL-10 induction in monocytes. PLoS One 7(9):e44900. doi: 10.1371/journal.pone.0044900 PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Liu WH, Liu JJ, Wu J, Zhang LL, Liu F, Yin L, Zhang MM, Yu B (2013) Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 8(1):e55487. doi: 10.1371/journal.pone.0055487 PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Al-Qahtani A, Al-Ahdal M, Abdo A, Sanai F, Al-Anazi M, Khalaf N, Viswan NA, Al-Ashgar H, Al-Humaidan H, Al-Suwayeh R, Hussain Z, Alarifi S, Al-Okail M, Almajhdi FN (2012) Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol 84(9):1353–1359. doi: 10.1002/jmv.23271 CrossRefPubMedGoogle Scholar
  46. 46.
    Rong Y, Song H, You S, Zhu B, Zang H, Zhao Y, Li Y, Wan Z, Liu H, Zhang A, Xiao L, Xin S (2013) Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inflammation 36(2):413–418. doi: 10.1007/s10753-012-9560-4 CrossRefPubMedGoogle Scholar
  47. 47.
    Li G, Zheng Z (2013) Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol. doi: 10.1007/s13277-013-0689-z Google Scholar
  48. 48.
    Gurtan AM, Sharp PA (2013) The role of miRNAs in regulating gene expression networks. J Mol Biol. doi: 10.1016/j.jmb.2013.03.007 PubMedCentralPubMedGoogle Scholar
  49. 49.
    Hatao F, Muroi M, Hiki N, Ogawa T, Mimura Y, Kaminishi M, K-i Tanamoto (2004) Prolonged Toll-like receptor stimulation leads to down-regulation of IRAK-4 protein. J Leukoc Biol 76(4):904–908CrossRefPubMedGoogle Scholar
  50. 50.
    Chen M, Sällberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, Billaud J-N, Milich DR (2005) Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 79(5):3016–3027PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17(1):1–14CrossRefPubMedGoogle Scholar
  52. 52.
    Yin W, Xu L, Sun R, Wei H, Tian Z (2012) Interleukin-15 suppresses hepatitis B virus replication via IFN-β production in a C57BL/6 mouse model. Liver Int 32(8):1306–1314CrossRefPubMedGoogle Scholar
  53. 53.
    Wang J, Wang X, Liu P (1999) Detection of serum TNF-alpha, IFN-beta, IL-6 and IL-8 in patients with hepatitis B. World J Gastroenterol 5(1):38–40PubMedGoogle Scholar
  54. 54.
    Wang YD, Zhao CY, Wang W, Shen C, Lu HZ, Zhang L, Yu WY, Zhou JY, Yan WZ (2012) Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients. Hepatogastroenterology 59(115):680–686. doi: 10.5754/hge12183 PubMedGoogle Scholar
  55. 55.
    Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H (2013) Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol 48(3):397CrossRefPubMedGoogle Scholar
  56. 56.
    Örmeci N (2003) Short-and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol 17(6):651–658CrossRefPubMedGoogle Scholar
  57. 57.
    Sprinzl MF, Russo C, Kittner J, Allgayer S, Grambihler A, Bartsch B, Weinmann A, Galle PR, Schuchmann M, Protzer U, Bauer T (2013) Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment. J Viral Hepat. doi: 10.1111/jvh.12189 PubMedGoogle Scholar
  58. 58.
    Cho I-R, Oh M, Koh SS, Malilas W, Srisuttee R, Jhun BH, Pellegrini S, Fuchs SY, Chung Y-H (2012) Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor. Int J Mol Med 29(4):581–586PubMedCentralPubMedGoogle Scholar
  59. 59.
    Wang X, Li Y, Mao A, Li C, Li Y, Tien P (2010) Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-&bgr; induction by disrupting the VISA-associated complex. Cell Mol Immunol 7(5):341–348PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Roberts BJ, Dragon JA, Moussawi M, Huber SA (2012) Sex-specific signaling through Toll-Like Receptors 2 and 4 contributes to survival outcome of Coxsackievirus B3 infection in C57Bl/6 mice. Biol Sex Differ 3(1):25. doi: 10.1186/2042-6410-3-25 PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Isogawa M, Robek MD, Furuichi Y, Chisari FV (2005) Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79(11):7269–7272. doi: 10.1128/JVI.79.11.7269- 7272.2005PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Heiberg IL, Winther TN, Paludan SR, Hogh B (2012) Pattern recognition receptor responses in children with chronic hepatitis B virus infection. J Clin Virol 54(3):229–234. doi: 10.1016/j.jcv.2012.04.013 CrossRefPubMedGoogle Scholar
  63. 63.
    Chen L, Xu YY, Zhou JM, Wu YY, E Q, Zhu YY (2012) TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells. Oncol Rep 28(1):200–206. doi: 10.3892/or 2012.1791PubMedGoogle Scholar
  64. 64.
    Schwarz K, Storni T, Manolova V, Didierlaurent A, Sirard JC, Rothlisberger P, Bachmann MF (2003) Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 33(6):1465–1470. doi: 10.1002/eji.200323919 CrossRefPubMedGoogle Scholar
  65. 65.
    Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46(6):1769–1778. doi: 10.1002/hep.21897 CrossRefPubMedGoogle Scholar
  66. 66.
    Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Daneshmandi S, Shamsizadeh A, Kennedy D (2011) Non-association of IL-12 +1188 and IFN-gamma +874 polymorphisms with cytokines serum level in occult HBV infected patients. Saudi J Gastroenterol 17(1):30–35PubMedCentralCrossRefPubMedGoogle Scholar
  67. 67.
    Dimitropoulou D, Karakantza M, Theodorou GL, Leonidou L, Assimakopoulos SF, Mouzaki A, Gogos CA (2013) Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers. World J Gastrointest Pathophysiol 4(1):24–27. doi: 10.4291/wjgp.v4.i1.24 PubMedCentralCrossRefPubMedGoogle Scholar
  68. 68.
    Xiang X, Gui H, King NJ, Cole L, Wang H, Xie Q, Bao S (2012) IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol 90(6):611–619. doi: 10.1038/icb.2011.79 CrossRefPubMedGoogle Scholar
  69. 69.
    Cao J, Zhang L, Huang S, Chen P, Zou L, Chen H, Xiang Y, Lai X, Ren G (2011) Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microb Pathog 51(4):262–267. doi: 10.1016/j.micpath.2011.06.003 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Masoud Karimi-Googheri
    • 1
  • Mohammad Kazemi Arababadi
    • 2
    Email author
  1. 1.Department of Immunology, Faculty of MedicineKerman University of Medical SciencesKermanIran
  2. 2.Immunology of Infectious Diseases Research CenterRafsanjan University of Medical SciencesRafsanjanIran

Personalised recommendations